Art

J-GLOBAL ID：201902272878682228   Reference number：19A0507562

Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol

EGFR変異を有する進行性非小細胞肺癌の化学療法患者におけるアファチニブ単独またはベバシズマブ併用の第2相試験:AFABEV-CS研究プロトコル【JST・京大機械翻訳】

Author (25)： Ninomiya Takashi (Health Service Center, Okayama University, Okayama, Japan) ,  Ninomiya Takashi (Department of Respiratory Medicine and Allergy, Okayama University Hospital, Okayama, Japan) ,  Ishikawa Nobuhisa (Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan) ,  Inoue Koji (Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan) ,  Kubo Toshio (Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan) ,  Yasugi Masayuki (Department of Respiratory, Chugoku Central Hospital, Fukuyama, Japan) ,  Shibayama Takuo (Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan) ,  Maeda Tadashi (Department of Medical Oncology, National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Japan) ,  Fujitaka Kazunori (Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan) ,  Kodani Masahiro (Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, Yonago, Japan) ,  Yokoyama Toshihide (Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan) ,  Kuyama Shoichi (Department of Respiratory Medicine, Iwakuni Clinical Center, Iwakuni, Japan) ,  Ochi Nobuaki (Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan) ,  Ueda Yutaka (Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Japan) ,  Miyoshi Seigo (Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine, Toon, Japan) ,  Kozuki Toshiyuki (Department of Thoracic Oncology and Medicine, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan) ,  Amano Yoshihiro (Department of Internal Medicine Division of Medical Oncology & Respiratory Medicine Shimane University Faculty of Medicine, Izumo, Japan) ,  Kubota Tetsuya (Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nangoku, Japan) ,  Sugimoto Keisuke (Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital, Kobe, Japan) ,  Bessho Akihiro (Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan) ,  Ishii Tomoya (Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan) ,  Watanabe Kazuhiko (Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan) ,  Oze Isao (Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan) ,  Hotta Katsuyuki (Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan) ,  Kiura Katsuyuki (Department of Respiratory Medicine and Allergy, Okayama University Hospital, Okayama, Japan)
Material： Clinical Lung Cancer
Volume： 20  Issue： 2  Page： 134-138  Publication year： 2019 
JST Material Number： W3210A  ISSN： 1525-7304  Document type： Article
Article type： 短報  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Afatinib, a second-generation ...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0507562&from=J-GLOBAL&jstjournalNo=W3210A") }}

Thesaurus term： *EGF receptor ,  combination therapy ,  toxicity ,  *non-small cell lung cancer ,  *phase 2 study ,  phase 1 study ,  *therapy ,  Mutation ,  effectiveness ,  end point ,  tyrosine kinase inhibitor ,  *Advanced non-small cell lung cancer
Semi thesaurus term： *ベバシズマブ , 【Automatic Indexing@JST】

Author keywords (3)： Anti-angiogenesis ,  EGFR-TKI ,  Molecular targeted therapy

JST classification (2)： Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Terms in the title (12)： EGFR ,  変異 ,  進行性非小細胞肺癌 ,  化学療法 ,  患者 ,  アファチニブ ,  ベバシズマブ ,  併用 ,  第2相試験 ,  Cs ,  研究 ,  プロトコル